

# Patrick Marcellin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1892611/publications.pdf>

Version: 2024-02-01

30  
papers

6,597  
citations

279487

23  
h-index

476904

29  
g-index

30  
all docs

30  
docs citations

30  
times ranked

6054  
citing authors

#	ARTICLE	IF	CITATIONS
1	Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. <i>Lancet</i> , The, 2013, 381, 468-475.	6.3	1,476
2	Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2008, 359, 2442-2455.	13.9	1,083
3	Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2004, 351, 1206-1217.	13.9	1,082
4	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 196-206.	3.7	377
5	Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. <i>Liver International</i> , 2018, 38, 2-6.	1.9	361
6	Combination of Tenofovir Disoproxil Fumarate and Peginterferon Î±-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2016, 150, 134-144.e10.	0.6	284
7	Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1457-1464.	1.1	249
8	Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 132-142.e4.	0.6	232
9	Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up. <i>Hepatology</i> , 2006, 44, 728-735.	3.6	221
10	Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current <sc>IFN</sc>-free treatment and future perspectives. <i>Liver International</i> , 2016, 36, 47-57.	1.9	193
11	Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. <i>Cancer</i> , 2015, 121, 3631-3638.	2.0	173
12	Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?. <i>Liver International</i> , 2018, 38, 7-13.	1.9	128
13	Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. <i>Journal of Hepatology</i> , 2017, 66, 39-47.	1.8	100
14	Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. <i>Liver International</i> , 2019, 39, 1868-1875.	1.9	97
15	<sc>HB</sc>sAg quantification: useful for monitoring natural history and treatment outcome. <i>Liver International</i> , 2014, 34, 97-107.	1.9	93
16	Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). <i>Journal of Hepatology</i> , 2016, 64, 1011-1019.	1.8	84
17	Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. <i>Liver International</i> , 2011, 31, 516-524.	1.9	64
18	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. <i>Journal of Hepatology</i> , 2015, 62, 41-47.	1.8	59

#	ARTICLE	IF	CITATIONS
19	<scp>HB</scp>sAg quantification to optimize treatment monitoring in chronic hepatitis B patients. Liver International, 2015, 35, 82-90.	1.9	56
20	Future treatments for hepatitis delta virus infection. Liver International, 2020, 40, 54-60.	1.9	37
21	Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life. Liver International, 2021, 41, 1509-1517.	1.9	35
22	Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B. Liver International, 2011, 31, 122-128.	1.9	33
23	Anti- $\epsilon$ pre-S responses and viral clearance in chronic hepatitis B virus infection. Hepatology, 1992, 15, 26-31.	3.6	24
24	Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. Clinical Gastroenterology and Hepatology, 2017, 15, 1087-1094.e2.	2.4	19
25	New therapies for hepatitis delta virus infection. Liver International, 2021, 41, 30-37.	1.9	17
26	Staging Fibrosis in Chronic Viral Hepatitis. Viruses, 2022, 14, 660.	1.5	8
27	Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. BMC Infectious Diseases, 2019, 19, 300.	1.3	5
28	Sofosbuvir + Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. Journal of Viral Hepatitis, 2020, 27, 964-973.	1.0	5
29	Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: A retrospective clinical-pathological study. Digestive and Liver Disease, 2015, 47, 296-302.	0.4	2
30	Update on the Role of Quantitative HBsAg and HBeAg Monitoring during Peginterferon Therapy. Current Hepatitis Reports, 2012, 11, 75-81.	0.3	0